|
Report Date : |
17.07.2012 |
IDENTIFICATION DETAILS
|
Name : |
SIZA INTERNATIONAL (PVT) LIMITED |
|
|
|
|
Registered Office : |
|
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
1978 |
|
|
|
|
Com. Reg. No.: |
0006462 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture & Marketing of Pharmaceutical
Products |
|
|
|
|
No. of Employees : |
180 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2012
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
Pakistan |
B2 |
B2 |
|
Risk Category |
ECGC Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SIZA INTERNATIONAL (PVT) LIMITED
|
Registered Address |
|
18 K.M. Main Ferozepur
Road, Lahore, Pakistan |
|
Tel # |
92 (42) 35811172, 35711369, 35763431 |
|
Fax # |
92 (42) 35812052 |
|
Email |
|
a. |
Nature of Business |
Manufacture
& Marketing of Pharmaceutical Products |
|
b. |
Year Established |
1978 |
|
c. |
Registration # |
0006462 |
65/2
Syed Maratib Ali Road,
FCC, Gulberg IV, Lahore,
Pakistan
|
Arshad Raheem
& Co. (Chartered
Accountants) 39-Link Farid Kot Road, Lahore, Pakistan |
|
Subject Company was established as a
Private Limited Company in 1978 |
|
6. |
Authorized
Capital |
Rs. 30,000,000/- divided into 300,000 shares of Rs. 100/- each |
|
|
Issued & Paid
up Capital |
Rs. 16,875,200/- divided into 168,752 shares of Rs. 100/- each |
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr.
Khawaja Muhammad Zahid Mr.
Muhammad Iqbal Mr.
Muhammad Saboor Mr.
Muhammad Saeed Mr.
Muhammad Sadiq Mr.
Khawaja Raza Zahid Mr.
Khawaja Muhammad Arif Mr.
Khawaja Muhammad Asif Razee |
Pakistani Pakistani Pakistani Pakistani Pakistani Pakistani Pakistani Pakistani |
18
K.M. Main Ferozepur Road, Lahore 18
K.M. Main Ferozepur Road, Lahore 18
K.M. Main Ferozepur Road, Lahore 18
K.M. Main Ferozepur Road, Lahore 18
K.M. Main Ferozepur Road, Lahore 18
K.M. Main Ferozepur Road, Lahore 18
K.M. Main Ferozepur Road, Lahore 18
K.M. Main Ferozepur Road, Lahore |
Business Business Business Business Business Business Business Business |
Chief
Executive Director Director Director Director Director Director Director |
|
Names |
No.
of Shares |
|
Mr.
Khawaja Muhammad Zahid Mr.
Muhammad Iqbal Mr.
Muhammad Saboor Mr.
Muhammad Saeed Mr.
Muhammad Sadiq Mr.
Khawaja Raza Zahid Mr.
Khawaja Muhammad Arif Mr.
Khawaja Muhammad Asif Razee Mrs.
Misbah Arif |
24,688 19,219 26,719 19,219 19,219 17,500 36,813 1,250 4,125 |
A. Subsidiary
None
B. Associated Companies
(1) Lahore
Medical Instruments (Pvt) Limited, Pakistan.
|
Manufacture
& marketing of different pharmaceutical class like Anti Biotic, Anti
Malarials, Anti-Rheumatic, Antihistamine, Narcotic Analgesic, Non Steroidal
Respiratory Anti Inflamatory, Quinolones, Vitamins, Phenothiazine, Hypolipidaemics,
Muscle Relaxant, Amoebicide, Calcium-Antagonist, Cardio Selective Beta
Blocker with their brand names of ADOLAN, AHYAL, ALEREAS, ALODINE, ALOVAC,
AMOR, AMRX, AMYLINE, ANASYNTH, APAROX, AQUASIN, ASMATOL, ASTEMINE, ASTHANIL,
AVITA, BIKIL, BISON, CLOPAN, CLOTRIMA, CONVUL, CYPRODIN, DEOCALM, DEVOM,
DIABETA, DIPYRON, DUPOPHEN, ELOVIR, EMETIL, EMOTIVAN, EPINAT, GARAN, IMIDOL,
INDOCIN, LIMBAR, LIVIAT, LOMPER, LORICIN, LOXAT, MAVEST, MAYADIL, MEGAVIT,
METROZIL, MEXAIR, NAUSIN, NEOLOX, NEOSTIG, NIFELAT, NOCTRUM, NUMBAIX,
OBRAMYCIN, PARACETAMOL, PRAVA, RANITIDE, RHEUMATIN, ROTAVIT, SAURAN, SIZADOX,
SOLVEIN, SOPRA, STYFEN, SUCFATE, WORMAZOLE, XIVAL, ZEEFRA, ZEMYCARD |
180
|
The capacity and
production of the Company’s plant is indeterminable as it is
multi-product and involves varying processes of manufacture. |
|
Year |
In Pak Rupees |
|
2010 |
220,000,000/- (Estimated) |
|
(1) BASELL POLYOLEFINS,
BELGIUM. (2) SHADONG
PHARMACEUTICALS, CHINA. |
|
Mainly exist at
major cities of Pakistan |
|
(1) MCB Bank Limited,
Pakistan. (2) Habib Bank
Limited, Pakistan. (3) Bank Alfalah
Limited, Pakistan. (4) Faysal Bank Limited, Pakistan. (5) United Bank Limited, Pakistan. |
Lahore Chamber of Commerce & Industry.(LCCI)
Pakistan
Pharmaceutical Manufacturers Association.(PPMA)
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs.
94.80 |
|
UK Pound |
1 |
Rs.
146.70 |
|
Euro |
1 |
Rs.
116.10 |
Subject Company
was established in 1978 and is engaged in manufacture & marketing of Pharmaceutical
Products. Directors are reported as resourceful and experienced businessmen.
Trade relations are reported as fair. Subject can be considered for normal
business dealings at usual trade terms and conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.54.92 |
|
|
1 |
Rs.85.47 |
|
Euro |
1 |
Rs.67.15 |
INFORMATION DETAILS
|
Report Prepared
by : |
PDT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.